The aggressive peripheral T‐cell lymphomas: 2015

Background: T‐cell lymphomas make up approximately 10%–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  R. Advani,et al.  Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL) , 2014 .

[3]  W. Wilson,et al.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. , 2014, Blood.

[4]  S. Pileri,et al.  Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. , 2014, The oncologist.

[5]  Jeffrey W. Clark,et al.  Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  A. Zelenetz,et al.  A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. , 2013, Clinical lymphoma, myeloma & leukemia.

[7]  Y. Kwong,et al.  How I treat NK/T-cell lymphomas. , 2013, Blood.

[8]  L. Geskin,et al.  Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders. , 2013, The oncologist.

[9]  N. Reddy,et al.  Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  A. Zelenetz,et al.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. , 2007, Clinical lymphoma, myeloma & leukemia.

[11]  J. Delabie,et al.  Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Naoe,et al.  EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. , 2012, Blood.

[13]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Advani,et al.  Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update , 2011 .

[15]  I. Lossos,et al.  Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL) , 2011 .

[16]  A. Nademanee,et al.  High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  B. Nathwani,et al.  Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. , 2011, Blood.

[18]  R. Champlin,et al.  Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  S. Steinberg,et al.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.

[20]  A. Zelenetz,et al.  FDG-PET in the staging and prognosis of T-cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Houot,et al.  18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Messa,et al.  Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.

[24]  Y. Ko,et al.  The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study. , 2010 .

[25]  J. Delabie,et al.  Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01) , 2010 .

[26]  F. Russo,et al.  Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial. , 2010 .

[27]  W. Chan,et al.  Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) , 2010 .

[28]  A. Rosenwald,et al.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.

[29]  T. Reiman,et al.  Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma , 2010, Cancer.

[30]  L. Pace,et al.  Assessment of metabolic activity by PET‐CT with F‐18‐FDG in patients with T‐cell lymphoma , 2010, British journal of haematology.

[31]  A. Attarbaschi,et al.  Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Advani,et al.  Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. , 2010 .

[33]  P. Gaulard,et al.  Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial--A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2010 .

[34]  S. Proctor,et al.  Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. , 2010, Blood.

[35]  T. Tsuzuki,et al.  Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  D. Patterson,et al.  Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. , 2010, Clinical lymphoma, myeloma & leukemia.

[37]  P. Gaulard,et al.  Advances in the understanding and management of angioimmunoblastic T‐cell lymphoma , 2010, British journal of haematology.

[38]  W. Chan,et al.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. , 2010, Blood.

[39]  Patrick Lutz,et al.  Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Schmitz,et al.  Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Verstovsek,et al.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  A. Feldman,et al.  Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas , 2008, Leukemia.

[43]  M. Djokic.  ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project , 2009 .

[44]  D. de Jong,et al.  Anaplastic large-cell lymphoma in women with breast implants. , 2008, JAMA.

[45]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Pek-Lan Khong,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies , 2008, Annals of Hematology.

[47]  R. Brezinschek,et al.  Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  P. Gaulard,et al.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2008, Blood.

[49]  P. Marlton,et al.  Post‐transplant hepatosplenic T‐cell lymphoma successfully treated with hyperCVAD regimen , 2008, American journal of hematology.

[50]  D. Sahani,et al.  Case records of the Massachusetts General Hospital. Case 8-2008. A 33-year-old man with fever, abdominal pain, and pancytopenia after renal transplantation. , 2008, The New England journal of medicine.

[51]  N. Schmitz,et al.  High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation , 2008 .

[52]  D. Aguiar Bujanda.  Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  S. Pileri,et al.  Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. , 2007, Blood.

[54]  K. Ohtomo,et al.  FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Christian Gisselbrecht,et al.  The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. , 2007, Blood.

[56]  R. Gascoyne,et al.  Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. , 2007, Gastroenterology.

[57]  R. Advani,et al.  Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine , 2007, Leukemia & lymphoma.

[58]  J. Armitage,et al.  F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas , 2007, Leukemia & lymphoma.

[59]  Y. Yamashita,et al.  Hepatosplenic alphabeta T-cell lymphoma successfully treated with allogeneic bone marrow transplantation. , 2007, Bone marrow transplantation.

[60]  Shulian Wang,et al.  Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  P. Gaulard,et al.  Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution. , 2005 .

[62]  I. Bruns,et al.  Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab , 2005, Leukemia.

[63]  Terry L. Smith,et al.  Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma , 2005, Cancer.

[64]  W. Au,et al.  Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. , 2004, Blood.

[65]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[66]  R. Feddersen,et al.  Anaplastic large cell lymphoma arising in a silicone breast implant capsule: a case report and review of the literature. , 2009, Archives of pathology & laboratory medicine.

[67]  P. Gaulard,et al.  Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients , 2003 .

[68]  A. Neugut,et al.  Risk of malignancy in patients with celiac disease. , 2003, The American journal of medicine.

[69]  P. Gaulard,et al.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. , 2003, Blood.

[70]  H. Müller-Hermelink,et al.  Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. , 2002, The American journal of pathology.

[71]  K. Ohshima,et al.  L-Asparaginase Induced Durable Remission of Relapsed Nasal NK/T-Cell Lymphoma After Autologous Peripheral Blood Stem Cell Transplantation , 2001, International journal of hematology.

[72]  M. Gulley,et al.  Hepatosplenic αβ T-cell lyrnphomas: A report of 14 cases and comparison with hepatosplenic γδ T-cell lymphomas , 2001 .

[73]  A. Grigg,et al.  2′-Deoxycoformycin for Hepatosplenic γδ T-Cell Lymphoma , 2001 .

[74]  M. Gulley,et al.  Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. , 2001, The American journal of surgical pathology.

[75]  D. Wright,et al.  Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Manning,et al.  Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases , 2000, Leukemia & lymphoma.

[77]  Y. Kwong,et al.  Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. , 1999, The American journal of pathology.

[78]  A. Chott,et al.  Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. , 1998, The American journal of pathology.

[79]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[81]  P. Gaulard,et al.  Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. , 1997, Blood.

[82]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[83]  J. Diebold,et al.  CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. , 1997, Blood.

[84]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[85]  T. Greiner,et al.  Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. , 1996, Blood.

[86]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[87]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[88]  M. Engelhard,et al.  Treatment of Angioimmunoblastic Lymphadenopathy (AILD)-Type T-Cell Lymphoma Using Prednisone with or without the COPBLAM/IMVP-16 Regimen , 1992, Annals of Internal Medicine.

[89]  J. Greally,et al.  COELIAC DISEASE AND MALIGNANCY , 1983, The Lancet.

[90]  B. Cooper,et al.  INTESTINAL LYMPHOMA ASSOCIATED WITH MALABSORPTION , 1978, The Lancet.

[91]  M. Yaron,et al.  Letter: Levamisole in rheumatoid arthritis. , 1976, Lancet.

[92]  K. Lennert,et al.  Cytological and functional criteria for the classification of malignant lymphomata. , 1975, The British journal of cancer. Supplement.

[93]  R. Lukes,et al.  Immunologic characterization of human malignant lymphomas , 1974, Cancer.

[94]  G. Frizzera,et al.  Angio-immunoblastic lymphadenopathy with dysproteinaemia. , 1974, Lancet.

[95]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.